Liraglutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
Liraglutide is a GLP-1 receptor agonist marketed for type 2 diabetes and weight loss. Human evidence here is genuinely strong, backed by large trials showing glycemic control, weight loss, and cardiovascular risk reduction. Tradeoffs include common GI side effects, gallbladder and pancreatitis risk, and a boxed thyroid tumor warning barring those with medullary thyroid cancer history. It is FDA-approved (Saxenda, Victoza), not a gray-market peptide.
Read Full recordStudied uses & evidence
Studied uses(7)
Type 2 diabetes glycemic control
HighLarge phase 3 trials showed HbA1c reductions of about 1 to 1.5 percentage points.
Significant weight loss
HighLarge 56-week trial showed average weight loss of 8.4 kg versus 2.8 kg with placebo.
Cardiovascular risk reduction
HighLarge cardiovascular outcomes trial in high-risk type 2 diabetes patients showed reduced major cardiac events.
Evidence limits
- Evidence Level
- Level 1 — Strong
Over 25,000 participants across Phase 3 programs (LEAD, SCALE, LEADER). Strong evidence for glycemic control, weight loss, CV risk reduction, and renal protection. 9,340-patient LEADER CVOT with 3.8-year follow-up is the cornerstone trial.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteFDA boxed warning: thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.
History of pancreatitis
HighPost-marketing cases of acute pancreatitis including fatal hemorrhagic pancreatitis reported.
Severe gastroparesis
HighSlows gastric emptying. Patients with gastroparesis excluded from clinical trials.
Severe renal impairment
ModerateGI side effects may cause dehydration and acute kidney injury. Monitor renal function.
General cautions
Pregnancy
AbsoluteAnimal studies indicate potential fetal harm. Discontinue Saxenda when pregnancy is recognized. FDA labeling does not specify a two-month preconception interval for liraglutide.
Risk summary(10)
Risks = level of concern: High · Moderate · Low · Theoretical
GI side effects: nausea, diarrhea, vomiting, decreased appetite, constipation (most common, affecting 20-40%)
HighHypoglycemia risk when combined with insulin or sulfonylureas; dose reduction of co-administered agents may be needed
HighGallbladder disease: cholelithiasis occurred in 2.2% versus 0.8% with placebo in Saxenda adult trials; cholecystitis occurred in 0.8% versus 0.4%. LEADER acute gallbladder events were 3.1% versus 1.9%.
ModerateElevated resting heart rate: 4-9 bpm increase; reports of tachycardia >100 bpm
ModerateBoxed warning: thyroid C-cell tumors in rodent studies at clinically relevant doses; contraindicated in MTC/MEN 2 patients
ModerateAcute pancreatitis risk (<0.4% of patients); discontinue if suspected
ModerateAcute kidney injury: postmarketing reports, usually secondary to dehydration from GI effects
LowHistorical reports of suicidal behavior and ideation prompted review, but FDA found no increased risk and the Saxenda warning was removed in February 2026.
TheoreticalHypersensitivity reactions: anaphylaxis and angioedema reported (rare)
LowInjection site reactions: erythema, pruritus, nodule formation
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.